Bone Biologics Launches $9M ATM Private Placement at $1.42 Per Share
BBLG•Bone Biologics will issue 2.11 million shares and warrants at $1.42 each in an ATM private placement for $3 million upfront and up to $6 million more upon warrant exercises, totaling $9 million in gross proceeds. Proceeds will fund clinical trials, patent portfolio expansion and general working capital needs.
1. Financing Overview
Bone Biologics entered a definitive agreement for an at-the-market private placement of 2,112,677 common shares or pre-funded warrants and accompanying Series F and Series G warrants at $1.42 per unit, raising approximately $3 million upfront with potential for $6 million in additional proceeds.
2. Warrant Terms and Expiration
Each Series F and Series G warrant grants the right to purchase one share at $1.42, exercisable following stockholder approval and registration effectiveness, with Series F warrants expiring five years from that date and Series G warrants expiring 18 months thereafter.
3. Use of Proceeds
Net proceeds are earmarked to support ongoing clinical trials, extend and maintain the company’s patent portfolio and provide working capital and general corporate funding to advance its orthobiologic product pipeline.
4. Closing and Conditions
The offering is expected to close on or about July 9, 2026, subject to customary closing conditions, and the company will file a registration statement to cover resale of the shares underlying the warrants under a registration rights agreement.
